AlterH.J., HollandP.V., PurcellR.H.Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med1972; 77: 691–9.
2.
FeinstoneS.M., KapikianA.Z., PurcellR.H., AlterH.J., HollandP.V.. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med1975; 292: 767–70.
3.
ChooQ.L., KuoG., WeinerA.J., OverbyL.R., BradleyD.W.. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244: 359–62.
4.
SimmondsP.. Variability of hepatitis C virus. Hepatology1995; 21: 570–83.
5.
KozielM.J.. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat1997; 4(suppl. 2): S31–41.
6.
McQuillanG.M., AlterM.J., MoyerL.A., LambertS.B., MargolisH.S.. A population based serologic study of hepatitis C virus infection in the United States. In: RizzettoM., PurcellR.H., GerinJ.L., VermeG., eds. Viral hepatitis and liver disease.Turin: Edizioni Minerva Medica, 1997; 267–70.
7.
WongJ.B., McQuillanG.M., McHutchisonJ.G., PoynardT.. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health2000; 90: 1562–9.
8.
AlterM.J.. Epidemiology of Hepatitis C. Hepatology1997; 26: (suppl) S62–65.
9.
AlterM.J., HadlerS.C., JudsonF.N.Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA1990; 264: 2231–5.
10.
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR1998; 47: 1–39.
11.
GarfeinR.S., VlahovD., GalaiN., DohertyM.C., NelsonK.E.. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Pub Health1996; 86: 656–61.
12.
Conry-CantilenaC., VanradenM., GibbleJ.Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med1996; 334: 1691–6.
13.
AlterM.J., ColemanP.J., AlexanderW.J.Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA1989; 262: 1201–5.
14.
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR1998; 47: 1–39.
15.
AlterM.J.. Epidemiology of hepatitis C in the west. Semin Liver Dis1995; 15: 5–14.
16.
MeleA., SaglioccaL., ManzilloG.Risk factors for acute non-A, non-B hepatitis and their relationship to antibodies for hepatitis C virus: a case-control study. Am J Public Health1994; 84: 1640–3.
17.
AlterM.J., MastE.E., MoyerL.A., MargolisH.S.. Hepatitis C. Infect Dis Clin North Am1998; 12: 13–26.
18.
AlterM.. Community acquired viral hepatitis B and C in the United States. Gut1993; S17–S19.
19.
GiustiG., PasqualeG., GalanteD.Clinical and histological aspects of chronic HCV infection and cirrhosis. Hepatogastroenterology1993; 40: 365–9.
20.
MazzaroC., ZagonelV., MonfardiniS.Hepatitis C and non-Hodgkin's lymphomas. Br J Haematol1996; 94: 544–50.
21.
HaddadJ., DenyP., Munz-Gotheil. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet1992; 339: 321–3.
22.
HoofnagleJ.H.. Hepatitis C: The clinical spectrum of disease. Hepatology1997; 26: 15S–20S.
23.
MattsonL., WeilandO., GlaumannH.. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome. Liver1988; 8: 184–8.
24.
HaydonG.H., JarvisL.M., SimmondsP.Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut1997; 40: 128–32.
25.
LokA.S., ChienD., ChooQ.L.Antibody response to core, envelope and nonstructural hepatitis C virus antigen: Comparison of immunocompetent and immunosuppressed patients. Hepatology1993; 18: 497–502.
26.
GretchD., dela RosaC., CarithersR.Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications. Ann Intern Med1995; 123: 321–9.
27.
PawlotskyJ-M. Measuring hepatitis C viremia in clinical samples: can we trust the assays?Hepatology1997; 26: 1–4.
28.
DavisG.L., HoofnagleJ.H.. Interferon in viral hepatitis: Role in pathogenesis and treatment. Hepatology1986; 6: 1038.
29.
TïnéF., MagrinS., CraxiA.Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J Hepatol1991; 13: 192.
30.
PoynardT., BedossaP., ChevallierM.A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med1995; 332: 1457.
31.
BodenheimerH.C., LindsayK.L., DavisG.L.Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology1997; 26: 473–7.
32.
McHutchisonJ.G., GordonS.C., SchiffE.R.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med1998; 339: 1485–92.
33.
PoynardT., MarcellinP., LeeS.S.Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet1998; 352: 1426–32.
34.
HeathcoteJ., ShiftmanM.L., CooksleyG.Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med2000; 343: 1673–80.
35.
ZeuzemS., FeinmanS.V., RasenackJ.Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med2000; 343: 1666–72.
36.
MannsM.P., McHutchisonJ.G., GordonS.Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 weeks treatment analysis of a multicenter, multinational phase III randomized controlled trial (Abstract). Hepatology2000; 325 [4 part 2]: 297A. Abstract 552.
37.
European Association for the Study of the Liver. International Consensus Conference on Hepatitis. Consensus statement. J Hepatol1999; 31(suppl. 1): S3–8.
38.
National Institute of Health Consensus Development Conference Panel: Statement: Management of hepatitis C. Hepatology1997; 26(suppl. 1): S2–10.
39.
PoynardT., McHutchisonJ., GoodmanZ.Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for first line treatment in patients with chronic hepatitis C?Hepatology2000; 31: 211–8.
